RxDoctor Payments Data

Lawrence Owusu, PA

Medical · Oceanside, CANPI 1720185614

Payments from drug & device makers

$7,968in general payments, 2019–2025

Across 256 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$3K
  • Abbott$865
  • Boston Scientific$537
  • Collegium Pharmaceutical, Inc.$407
  • Nalu Medical, Inc.$331
  • Painteq LLC$267
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$1,67421%
  • Food & beverage$6,29479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,968 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$120,832
Medicare patients
193
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl125$96,213
Xtampza ErOxycodone Myristate89$48,311
Nucynta ErTapentadol Hcl12$20,772
OxycontinOxycodone Hcl37$16,304
NucyntaTapentadol Hcl15$15,969
Buprenorphine45$12,991
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen399$12,781
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen481$11,858
Fentanyl74$7,367
Hysingla ErHydrocodone Bitartrate11$5,760
Tramadol Hcl ErTramadol Hcl50$5,391
Oxycodone Hcl259$4,924
Hydromorphone Hcl155$4,607
Morphine Sulfate ErMorphine Sulfate157$4,457
Duloxetine Hcl249$4,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta$407$181,264241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →